252 filings
Page 8 of 13
8-K
0wtpgm9lm
24 Oct 14
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
12:00am
8-K
jov7s5y0r6hzfl9go5g
24 Sep 14
Cellceutix Provides Update to Shareholders
12:00am
8-K
89imnnz6z059qy
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
UPLOAD
mt2v ttpu5hl187
18 Mar 14
Letter from SEC
12:00am
CORRESP
gb83y2
4 Mar 14
Correspondence with SEC
12:00am
UPLOAD
c9b8aa4
25 Feb 14
Letter from SEC
12:00am
424B3
kr0zckv4o4l 7nq
22 Nov 13
Prospectus supplement
12:00am
EFFECT
faeguc9
14 Nov 13
Notice of effectiveness
12:00am
8-K
6dyfhp9x
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
NT 10-K
0kk 9jmq3kqu
13 Sep 13
Notice of late annual filing
12:00am
8-K
kidbwefxy bq5239
9 Sep 13
Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets
12:00am
8-K
dct2ndmmfw xg402v29
5 Jun 13
Changes in Registrant's Certifying Accountant
12:00am